Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-variant inhibitor for activating and resistance mutations of the KIT kinase or a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
IPO Year: 2004
Exchange: NASDAQ
Website: theseusrx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/14/2023 | Buy → Hold | Needham | |
| 3/16/2023 | $24.00 | Buy | Stifel |
| 12/14/2022 | $22.00 | Buy | Needham |
| 6/30/2022 | $22.00 | Buy | H.C. Wainwright |
| 11/1/2021 | $25.00 | Overweight | Cantor Fitzgerald |
| 11/1/2021 | $24.00 | Outperform | Wedbush |
| 11/1/2021 | $28.00 | Outperform | SVB Leerink |
| 11/1/2021 | $23.00 | Buy | Jefferies |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Needham downgraded Theseus Pharmaceuticals from Buy to Hold
Stifel initiated coverage of Theseus Pharmaceuticals with a rating of Buy and set a new price target of $24.00
Needham initiated coverage of Theseus Pharmaceuticals with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Theseus Pharmaceuticals with a rating of Buy and set a new price target of $22.00
Cantor Fitzgerald initiated coverage of Theseus Pharmaceuticals with a rating of Overweight and set a new price target of $25.00
Wedbush initiated coverage of Theseus Pharmaceuticals with a rating of Outperform and set a new price target of $24.00
SVB Leerink initiated coverage of Theseus Pharmaceuticals with a rating of Outperform and set a new price target of $28.00
Jefferies initiated coverage of Theseus Pharmaceuticals with a rating of Buy and set a new price target of $23.00
15-12G - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
EFFECT - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
S-8 POS - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
S-8 POS - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
POS AM - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
8-K - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
SC 14D9/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
25-NSE - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
SC 14D9/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
SC 14D9/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
Fastest customizable press release news feed in the world
-- Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right -- CAMBRIDGE, Mass., Feb. 14, 2024 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that Concentra Biosciences, LLC ("Concentra") through its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of Theseus common stock for a price per share of (i) $4
As previously announced on December 22, 2023, Concentra Biosciences, LLC ("Parent") and its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Purchaser"), entered into a merger agreement (the "Merger Agreement") with Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus") whereby Purchaser will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 per share (the "Base Price") and (ii) an additional cash amount of up to $0.15 per share (the "Additional Price Per Share" and together with the Base Price, the "Cash Amount"), plus one non-tradeable contingent value right ("CVR")
CAMBRIDGE, Mass., Dec. 22, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ("Concentra") will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") of between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 per share (the "Base Price") and (ii) an additional cash amount of not more
CAMBRIDGE, Mass., Nov. 27, 2023 /PRNewswire/ -- On November 22, 2023, the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company) received an unsolicited joint letter from funds and persons affiliated with Foresite Capital, LLC (collectively, Foresite) and funds and persons affiliated with OrbiMed Advisors LLC (collectively, OrbiMed), in which Foresite and OrbiMed indicated their intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock of the Company not already owned by Foresite or OrbiMed in a going-private transaction. On November 24, 2023, the Board also received an unsolicited proposal from Ta
CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that it is conducting a process exploring strategic alternatives to maximize shareholder value. In conjunction with the strategic process, Theseus implemented a workforce reduction of approximately 72%. This includes Theseus' President of Research and Developm
IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024 Nomination of highly selective pan-variant KIT inhibitor candidate for GIST expected in H1 2024 Announces plans to explore the development of low dose THE-630 in mast cell-driven inflammatory indications based on dose-dependent reductions in serum tryptase levels in patients in GIST study $234.2 million of cash, cash equivalents, and marketable securities as of June 30, 2023 CAMBRIDGE, Mass., Aug. 10, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company f
-- Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) -- -- Company prioritizing THE-349, a potentially best-in-class fourth-generation EGFR inhibitor for EGFR mutant non-small cell lung cancer; IND on track for submission in Q4 2023 -- -- Theseus announces new program targeting KIT for patients with early-line GIST; development candidate nomination expected in the H1 2024 -- -- Development candidate nomination from BCR-ABL program also expected in H1 2024 -- -- $234 million in cash, cash equivalents, and marketable securities as of June 30, 2023; runway extended into 2026 -- CAMBRIDGE, Mass., July 13, 2023 /PRNewswire/ -- Theseus Ph
CAMBRIDGE, Mass., May 31, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate in a live Fireside Chat at the Jefferies Healthcare Conference on June 8th at 10:30am ET. A live webcast will be available in the Events section of the company's investor relations website at ir.theseusrx.com and archived for 30 days following the presentation. About Theseus Pharmaceuticals, Inc.Theseus is a clinical-stage biopharmaceutical company focused
-- THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation -- -- Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for both major classes of KIT resistance mutations at exposures consistent with preclinical predictions observed in Predictive Resistance Assay™ -- -- Evidence of clinical activity observed in heavily pre-treated patient population at exposures below target, with 8 out of 9 evaluable patients treated in Cohorts 4-6 (9 to 18 mg) achieving stable disease -- -- Dose escalation ongoing to achieve target exposure of 100 nM predicted for pan-variant KIT activity, projected in Cohort 8 (40 mg) -- -- Compan
-- THE-630 initial dose escalation data to be presented at investor event on May 25, 2023, with additional dose escalation data expected in Q4 2023 -- -- IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023; development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected by early 2024 -- -- $243.6 million of cash, cash equivalents, and marketable securities as of March 31, 2023, with runway projected into Q3 2025 -- CAMBRIDGE, Mass., May 11, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, an
Live Leadership Updates
All sites open and actively enrolling in Phase 1 portion of Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose escalation data expected in Q2 2023 Preclinical data characterizing THE-349 in EGFR-mutant NSCLC presented at 2022 EORTC-NCI-AACR Symposium; IND application submission expected in H2 2023 $221.0 million in cash, cash equivalents, and investments as of September 30, 2022; expected to fund operations into the fourth quarter of 2024 CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, deve
CAMBRIDGE, Mass., Oct. 19, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced the appointment of Steven Stein, M.D. to its Board of Directors. "We are delighted to welcome Dr. Stein to the Theseus Board as we advance development of our THE-630 and THE-349 programs, while also expanding our early-stage pipeline," said Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus. "Dr. Stein's depth and breadth of oncology expertise, and extens
THE-630 Phase 1/2 clinical trial enrolling patients; initial data expected in Q2 2023 Nomination of development candidate for fourth-generation epidermal growth factor receptor (EGFR) inhibitor program expected in Q3 2022; IND expected in 2023 $228.6 million in cash, cash equivalents, and investments as of June 30, 2022; expected to fund operations into the fourth quarter of 2024 CAMBRIDGE, Mass., Aug. 11, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today anno
CAMBRIDGE, Mass., May 18, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced the appointment of Don Hayden to its Board of Directors. "We are thrilled to welcome Don as a tremendous addition to the Theseus Board. Don is a recognized, deeply experienced leader in the industry, and he will bring a unique perspective to Theseus as we advance our Phase 1/2 clinical trial of THE-630 in patients with GIST and expect to file an IND for our second program in E
This live feed shows all institutional transactions in real time.
SC 13D/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
SC 13G/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
SC 13D/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
SC 13D/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
SC 13D/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
SC 13D/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
SC 13D/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
SC 13D - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
SC 13G/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
SC 13D/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)